As a result of CLSA’s advocacy efforts, 35 members of the California delegation signed on to a letter urging for an increase of at least $2.2 billion for the National Institutes of Health (NIH) as part of this year’s congressional appropriations process.
On March 12, the California State Assembly released its report summarizing findings and recommendations from six hearings held by the Assembly’s Select Committee on Health Care Delivery Systems and Universal Coverage over the past few months.
Last month, CLSA President & CEO, Sara Radcliffe, and our Federal Government Relations team participated in AdvaMed’s State MedTech Alliance (SMTA) annual fly-in to advocate for medical technology investment, innovation and jobs.
Last year, Governor Brown signed Senate Bill 17 (Hernandez) into law. The law requires manufacturers to provide a 60-day advance notice of any price increase on a drug to all California public agency purchasers, health insurers, and pharmacy benefit managers (PBM) if that drug’s price has increased 16 percent or more cumulatively over the previous two calendar years, including the current year’s increase.
The California Life Sciences Association (CLSA) invites you to join us for a roundtable discussion and lunch on Wednesday, April 4th, to discuss housing and infrastructure needs in South San Francisco.
CLSA’s seasoned federal government relations team is engaged on behalf of the biomedical, agriculture, and industrial biotechnology sectors in multiple ways through strategic collaborations and direct lobbying in Washington, D.C. to advance innovation, investment and job creation for California’s treasured life sciences ecosystem. Read CLSA’s 2018 federal policy goals here.
In 2018, CLSA will continue to direct and expand its one-of-a-kind locally-focused program throughout the state. CLSA expects to engage in local policy and advocacy in the following areas: Local Drugs/Sharps Take Back Legislation; Polystyrene/Styrofoam Bans; San Francisco Gross Receipts Tax (GRT); Transportation; Housing and Education.
On Feb. 7, CLSA held its annual Back to Session Reception to welcome legislators back to Sacramento for the commencement of another legislative year, as well as to honor those legislators identified by CLSA membership as Life Sciences Champions. Dozens of legislators and at least two hundred other attendees packed the Ella Dining Room and Bar to see the presentation and mingle with those representing the life sciences industry, among others.
This month (February 9), Congress passed and the President signed into law a full and permanent repeal of the Independent Payment Advisory Board (IPAB). Eliminating the IPAB is critical for the continued success of California’s innovative life sciences sector, because the board could have harmed biomedical innovation by reducing incentives for investment in new research and product development.